Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover

MLA

Caroline Wilson, et al. “Goserelin, as an Ovarian Protector during (Neo)Adjuvant Breast Cancer Chemotherapy, Prevents Long Term Altered Bone Turnover.” Journal of Bone Oncology, vol. 5, no. 1, Mar. 2016, pp. 43–49. EBSCOhost, https://doi.org/10.1016/j.jbo.2016.02.003.

APA

Caroline Wilson, Fatma Gossiel, Robert Leonard, Richard A Anderson, Douglas J A Adamson, Geraldine Thomas, & Robert E Coleman. (2016). Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover. Journal of Bone Oncology, 5(1), 43–49. https://doi.org/10.1016/j.jbo.2016.02.003

Chicago

Caroline Wilson, Fatma Gossiel, Robert Leonard, Richard A Anderson, Douglas J A Adamson, Geraldine Thomas, and Robert E Coleman. 2016. “Goserelin, as an Ovarian Protector during (Neo)Adjuvant Breast Cancer Chemotherapy, Prevents Long Term Altered Bone Turnover.” Journal of Bone Oncology 5 (1): 43–49. doi:10.1016/j.jbo.2016.02.003.